Skip to content
Synkrino Biotherapeutics logo

Synkrino Biotherapeutics

Synkrino Biotherapeutics is a YC Summer 2018 (S18) company. Based in Oakland, CA, USA. Team of 2.

  • AI-powered Drug Discovery
  • Biotech

About Synkrino Biotherapeutics

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Synkrino Biotherapeutics builds an AI-driven drug discovery system, SATIS, designed to identify therapeutic candidates without the biases that shape traditional discovery workflows. The platform targets the early-stage research bottleneck in biotech, replacing manual, hypothesis-constrained screening with automated, data-driven candidate identification.

From the Y Combinator listing

How Synkrino Biotherapeutics describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Synkrino's AI, SATIS is a powerful, unbiased discovery system for…

Facts

Industry
Healthcare / Healthcare -> Drug Discovery and Delivery
Location
Oakland, CA, USA
Team size
2
Status
Active
Stage
Early

Founders (2)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works